Home » Tardive Dyskinesia (TD) Treatment Drugs Market

Tardive Dyskinesia (TD) Treatment Drugs Market By Drug Type (Valbenazine, Deutetrabenazine) – Growth, Future Prospects And Competitive Analysis, 2017 – 2025

Price: $4999

Published: | Report ID: 10911 | Report Format : PDF

Market Insights

Tardive dyskinesia (TD) is a rare neurological disorder due to the long-term use of antipsychotic medications that act on dopamine receptors. It is anticipated that the TD treatment drugs market will show significant market growth over the forecast period owing to some factors, such as the increasing prevalence of TD, the higher number of unmet needs for the treatment of TD, and the expected launch of pipeline drugs. Although there are various drugs used in the treatment of TD, presently, only Valbenazine and Deutetrabenazine are approved by the FDA. Other drugs, such as benzodiazepines, botulinum toxin, amantadine, dopamine-depleting agents, calcium channel blockers, etc., are also used in the symptomatic relief of TD.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample
CTA Design Element 3

The report titled “Tardive dyskinesia (TD) Treatment Drugs Market: Growth, Future Prospects, and Competitive Analysis, 2018–2026” includes an in-depth analysis of the TD treatment drugs market for the period from 2016 to 2026. For the detailed market study, the TD treatment drugs market is categorized on the basis of drug types: valbenazine, deutetrabenazine, and other drugs (benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents, calcium channel blockers, etc.).

With a view to presenting an in-depth geographical study, the global TD treatment drugs market is segmented on the basis of key regional markets such as North America, Europe, Latin America, Asia Pacific, and the Middle East and Africa. For country-level analysis, the TD treatment drugs market is segmented into Canada, the United States, the United Kingdom, Germany, the rest of Europe, Mexico, Brazil, the rest of Latin America, China, Japan, the rest of Asia Pacific, the GCC, and the rest of the Middle East and Africa.

This report covers a detailed study of qualitative information along with statistical data for a better understanding of the current market situation and future market scenario. For a better understanding of the ongoing market trends and future market prospects, in-depth information about the market drivers, opportunities, and challenges of the global TD treatment drugs market is covered in the report. Attractive investment opportunities and a company profiling section provide detailed information on the key players in the global TD treatment drug market.

Based on drug types, the global tardive dyskinesia (TD) treatment drugs market is segmented as follows:

  • Valbenazine
  • Deutetrabenazine
  • Other

Tardive dyskinesia is a neurological movement disorder caused by long-term neuroleptic or anti-psychotic medication use. It is considered a rare disorder as it affects fewer than 200,000 people in the United States alone. Treatment of TD is highly individualized, and the first step is to minimize the use of neuroleptic drugs. Various types of drugs are used to alleviate the symptoms of TD, but only two drugs, valbenazine (Neurocrine Biosciences, Inc.) and deudeutetra benzine (Teva Pharmaceutical Industries, Ltd.), are approved by the US-FDA for the treatment of TD. It is estimated that valbenazine and deutetrabenazine will show significant market growth over the forecast period due to their clinically proven efficacy and target specificity. Other drugs, such as benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents, calcium channel blockers, etc., are also used to reduce the symptoms of TD. Prominent pipeline drugs such as SNC-102 (Synchroneuron) are expected to assist market growth during the forecast period of 2018–2026.

For the purpose of this study, the global tardive dyskinesia (TD) treatment drug market is categorized into three segments:

  • North America
    • United States
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of the Middle East and Africa

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Tardive dyskinesia is an anti-psychotic drug-induced movement disorder characterized by evidently abnormal, involuntary movements. Among the considered geographical markets, North America is the major revenue-contributing region in the global TD treatment drug market. Key factors facilitating the dominance of North America are early diagnosis, wide accessibility to treatment drugs, a greater number of affected people, and well-developed healthcare infrastructure. Studies have indicated that more than 50,000 patients are affected by TD in the United States. The ideal pipeline drug (SNC-102) and recent approvals of Valbenazine and Deutetrabenazine are expected to drive significant market growth in North America. The TD treatment drugs market in the Asia Pacific is set to capture a significant position on account of rising treatment awareness among the general population, the growing number of affected populations, and the developing healthcare infrastructure.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Tardive Dyskinesia (TD) Treatment Drugs Market Portraiture
2.1.1. Global Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2017 (US$ Mn)
2.1.2. Global Tardive Dyskinesia Treatment Drugs Market, by Geography, 2017 (Value %)

Chapter 3. Tardive Dyskinesia (TD) Treatment Drugs: Market Dynamics and Outlook
3.1. Market Definition and Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Tardive Dyskinesia (TD) Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Valbenazine
4.3. Deutetrabenazine
4.4. Other

Chapter 5. Global Tardive Dyskinesia (TD) Treatment Drugs Market, by Geography, 2016 – 2026
5.1. Overview
5.2. North America Tardive Dyskinesia Treatment Drugs Market Analysis, 2016 – 2026
5.2.1. North America Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
5.2.2. North America Tardive Dyskinesia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Tardive Dyskinesia Treatment Drugs Market Analysis, 2016 – 2026
5.3.1. Europe Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
5.3.2. Europe Tardive Dyskinesia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Tardive Dyskinesia Treatment Drugs Market Analysis , 2016 – 2026
5.4.1. Asia Pacific Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Tardive Dyskinesia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
5.4.2.1. China
5.4.2.2. Japan
5.4.2.3. Rest of APAC
5.5. Latin America Tardive Dyskinesia Treatment Drugs Market Analysis , 2016 – 2026
5.5.1. Latin America Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Tardive Dyskinesia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Tardive Dyskinesia Treatment Drugs Market Analysis, 2016 – 2026
5.6.1. MEA Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
5.6.2. MEA Tardive Dyskinesia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Auspex Pharmaceuticals
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Neurocrine Biosciences, Inc.
6.3. Synchroneuron Inc.
6.4. Teva Pharmaceutical Industries Ltd.
6.5. Other Notable Players

List of Figures

FIG. 1 Tardive Dyskinesia (TD) Treatment Drugs: Market Segmentation
FIG. 2 Global Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2017 (US$ Mn)
FIG. 3 Global Tardive Dyskinesia Treatment Drugs Market, by Geography, 2017 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography, 2017
FIG. 5 Market Competition Landscape, by Key Players, 2017
FIG. 6 Global Valbenazine Market, 2016 – 2026 (US$ Mn)
FIG. 7 Global Deutetrabenazine Market, 2016 – 2026 (US$ Mn)
FIG. 8 Global Other TD Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 9 U.S. Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 10 Canada Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 11 U.K. Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 12 Germany Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 13 Rest of Europe Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 14 Japan Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 15 China Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 16 Rest of Asia Pacific Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 17 Brazil Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 18 Mexico Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 19 Rest of Latin America Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 20 GCC Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)
FIG. 21 Rest of Middle East and Africa Tardive Dyskinesia Treatment Drugs Market, 2016 – 2026 (US$ Mn)

List of Tables

Table 1 Global Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
Table 2 North America Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
Table 3 North America Tardive Dyskinesia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
Table 4 Europe Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
Table 5 Europe Tardive Dyskinesia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
Table 6 Asia Pacific Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
Table 7 Asia Pacific Tardive Dyskinesia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
Table 8 Latin America Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
Table 9 Latin America Tardive Dyskinesia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)
Table 10 Middle East and Africa Tardive Dyskinesia Treatment Drugs Market, by Drug Type, 2016 – 2026 (US$ Mn)
Table 11 Middle East and Africa Tardive Dyskinesia Treatment Drugs Market, by Country, 2016 – 2026 (US$ Mn)

Frequently Asked Questions: 

What is the size of Tardive Dyskinesia (TD) Treatment Drugs Market?

The market for Tardive Dyskinesia (TD) Treatment Drugs is expected to reach US$ XX Bn in 2025.

What is the Tardive Dyskinesia (TD) Treatment Drugs Market CAGR?

The Tardive Dyskinesia (TD) Treatment Drugs market is expected to see significant CAGR growth over the coming years,at 3.7%.

What is the Forecast period considered for Tardive Dyskinesia (TD) Treatment Drugs Market?

The report is forecasted from 2017-2025.

What is the base year considered for Tardive Dyskinesia (TD) Treatment Drugs Market?

The base year of this report is 2016.

Who are the major players in this Market?

Auspex Pharmaceuticals,Neurocrine Biosciences, Inc.,Synchroneuron Inc.,Teva Pharmaceutical Industries Ltd.,Other Notable Players are some of the major players in the global market.

Eosinophilic Pneumonia Treatment Market

Published:
Report ID: 5486

Myelodysplastic Syndrome Market

Published:
Report ID: 32821

US Retail Pharmacy Market

Published:
Report ID: 32801

Basal Cell Carcinoma (BCC) Treatment Market

Published:
Report ID: 32698

Paroxysmal Nocturnal Hemoglobinuria Market

Published:
Report ID: 8654

Reversible Airway Diseases Treatment Market

Published:
Report ID: 32531

Pediatric Clinical Trials Market

Published:
Report ID: 32404

Pharmacovigilance Market

Published:
Report ID: 9503

France Retail Pharmacy Market

Published:
Report ID: 31153

Europe Pharma R&D Outsourcing Market

Published:
Report ID: 31143

U.S. Pharma R&D Outsourcing Market

Published:
Report ID: 30984

Pharma R&D Outsourcing Market

Published:
Report ID: 18993

Purchase Options

$2999
Delivery Format: Excel.
$4999
Designed for the individual purchaser.
$6999
Users located at a single corporate site or regional office.
$7999
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –


support

24/7 Research Support


– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN